ScholarLens Back to search
2011•Zhonghua zhongyiyao xuekanRequires access

Progress of RANK/RANKL/OPG system in Clinical Researches

Xiaolin Shi

Open publisher page 0 citations

Abstract

Nuclear factor-κB(RANK) and its ligand RANKL,belong to the tumor necrosis factor receptor activator(TNF) receptor ligand family member,after combination of both,the increased activity of osteoclasts,which lead to bone resorption.And osteoprotegerin(OPG) can compete RANKL with the RANK,inhibite the overexpression of osteoclasts,or interfere with bone marrow stromal cells and the interaction between osteoclasts and induce apoptosis of osteoclasts,RANK / RANKL / OPG system involved in bone resorption lead to a range of different diseases osteolytic lesions.Metabolic bone diseases about RANKL,OPG,come into the treatment provides a new target,is becoming one of the focuses of clinical researched.

About this research paper

What this paper is about

Nuclear factor-κB(RANK) and its ligand RANKL,belong to the tumor necrosis factor receptor activator(TNF) receptor ligand family member,after combination of both,the increased activity of osteoclasts,which lead to bone resorption.And osteoprotegerin(OPG) can compete RANKL with the RANK,inhibite the overexpression of osteoclasts,or interfere with bone marrow stromal cells and the interaction between osteoclasts and induce apoptosis of osteoclasts,RANK / RANKL / OPG system involved in bone resorption lead to a range of different diseases osteolytic lesions.Metabolic bone diseases about RANKL,OPG,come into the treatment provides a new target,is becoming one of the focuses of clinical researched.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Nuclear factor-κB(RANK) and its ligand RANKL,belong to the tumor necrosis factor receptor activator(TNF) receptor ligand family member,after combination of both,the increased activity of osteoclasts,which lead to bone resorption.And osteoprotegerin(OPG) can compete RANKL with the RANK,inhibite the overexpression of osteoclasts,or interfere with bone marrow stromal cells and the interaction between osteoclasts and induce apoptosis of osteoclasts,RANK / RANKL / OPG system involved in bone resorption lead to a range of different diseases osteolytic lesions.Metabolic bone diseases about RANKL,OPG,come into the treatment provides a new target,is becoming one of the focuses of clinical researched.

Key concepts: RANKL, Osteoprotegerin, RANK Ligand, Bone resorption, Stromal cell, Osteoclast, Tumor necrosis factor alpha, Activator (genetics)

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Progress of RANK/RANKL/OPG system in Clinical Researches — Research Paper | ScholarLens